Basophil

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Pharmaceutical, Health, Other Health, NDA, Apoptosis, Interleukin 5, AstraZeneca, Neutrophil, Ageing, CH2, Skin, B cell, Clinical trial, Sanofi, Basophil, Macrophage, Patient, FDA, Mergers and acquisitions, Benralizumab, New Drug Application, Therapy, Atopic dermatitis, Regeneron Pharmaceuticals, Drug discovery, Eosinophil, Discovery, News, Dupilumab, Pharmaceutical industry, Vaccine, Health care, Skin condition, Bullous pemphigoid, Phase

The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.

Key Points: 
  • The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.
  • It covers information about more than 5 companies and over 5 pipeline drugs related to Bullous Pemphigoid.
  • Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Bullous Pemphigoid pipeline landscape.
  • Overall, this report offers a comprehensive and detailed analysis of the Bullous Pemphigoid pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this skin disorder.

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Retrieved on: 
Monday, October 9, 2023
CSU, Basophil, Antibody, Biology, Inflammation, Apoptosis, Risk, Rockefeller, KOL, Stanford University School of Medicine, Survival, FCR, Microbiology, B cell, Transplant, Patient, Stem cell factor, Infection, Therapy, Stanford Institutes of Medicine Summer Research Program, CD117, Fraunhofer Society, Berlin, Immunology, Immunity, S-1 Executive Committee, Hives, Syndrome, Pharmacology, SCF, Rockefeller University, FC, Executive Committee, Translational medicine, Vaccine, Pathology, Dermatology, Allergy, Jasper

Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.

Key Points: 
  • Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.
  • Briquilimab is an unconjugated aglycosylated anti-c-Kit antibody that blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF).
  • This mechanism of action disrupts the critical survival signal, leading to mast cell apoptosis thereby removing the underlying source of the inflammatory response in chronic urticaria.
  • He is also a member of the Executive Committee of the Stanford Institute for Immunity, Transplantation and Infection.

Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board

Retrieved on: 
Wednesday, May 10, 2023
Asthma, MGH, Microbiology, Beth Israel Deaconess Medical Center, Basophil, Food allergy, Genomics, International Chinese Language Program, United States Air Force Scientific Advisory Board, Stanford University, Personalized medicine, Atopic dermatitis, Experimental pathology, Research, B cell, Harvard College, Cell, Assistant, Harvard Medical School, MDS, Galli, Immunity, Geisel School of Medicine, Division, Transplant, Executive Committee, Stanford University School of Medicine, Biology, Faculty, Knowledge, Immunology, BMS, S-1 Executive Committee, Hospital, Health, CD117, Massachusetts General Hospital, Therapy, Stanford Institutes of Medicine Summer Research Program, Anatomical pathology, Disease, Pathology

Professor at Stanford Medicine, to the company’s Scientific Advisory Board.

Key Points: 
  • Professor at Stanford Medicine, to the company’s Scientific Advisory Board.
  • “We are thrilled to welcome Dr. Galli to our Scientific Advisory Board,” said Ron Martell, CEO of Jasper Therapeutics.
  • “Dr.
  • Galli is an internationally recognized researcher who has made pioneering contributions to the field of immunology.

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Retrieved on: 
Monday, April 17, 2023
AACR, TNF, ITGB6, Neutrophil, Basophil, CRS, Therapeutic index, Pharmacokinetics, American Association for Cancer Research, Quality of life, IL-6, Head, Toxicity, Prostate, Neck, Lung, IL-2, Cytokine release syndrome, Patient, IL-8, SAN, Coagulation, Neoplasm, Lymphocyte, Research, Therapy, Tumor microenvironment, Vaccine

“TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.

Key Points: 
  • “TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.
  • “However, significant unmet needs remain as both the depth and the durability of response with antibody drug conjugates are typically limited.
  • For more details about the AACR Annual Meeting, please visit:
    The posters will be available on Harpoon’s website following today’s presentations.
  • This spatial control of activation may address on-target tissue damage, hence enabling an expansion of the T cell engager target space.

XOLAIR Drug Insights and Market Forecasts, 2019-2021 & 2022-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Pharmaceutical, Health, Clinical Trials, Clinical trial, Basophil, Syringe, IL-5, Omalizumab, Blood, Immunoglobulin G, Research, SWOT, Polyp (medicine), Inflammation, Downregulation and upregulation, SC, Eosinophil, B cell, Immunoglobulin E, FDA, Phase, United Kingdom, Asthma, CIU, Cell, Pharmaceutical industry, Vaccine, Petroleum jelly, Risk management, FCER1

"XOLAIR Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XOLAIR for Nasal Polyposis in the 7MM.

Key Points: 
  • "XOLAIR Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XOLAIR for Nasal Polyposis in the 7MM.
  • The report also highlights the XOLAIR research and development activity in Nasal Polyposis details across the United States, Europe and Japan.
  • What are the forecasted sales of XOLAIR in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available in Nasal Polyposis and how are they giving competition to XOLAIR for Nasal Polyposis?

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Retrieved on: 
Sunday, December 11, 2022
Enzyme, Flow cytometry, WBC, Primate, ASH, AML, Hematocrit, Toxicity, COVID-19, Basophil, Observation, Bilirubin, Form 10-K, Gemstone, NHP, Reticulocyte, Safety, Cancer, Antibody-drug conjugate, CD123, Workforce, Biosimilar, Society, Pandemic, Hematology, Therapy, Diffusion, ADC, Control, Venetoclax, Male, PALO, Patient, Azacitidine, Failure, Bone marrow, Myelocyte, 8-K, Toxic shock syndrome, Drug Quality and Security Act, Survival, Lymphocyte, IND, KSPI, Fine chemical, Pharmaceutical industry, Risk management, Gemtuzumab ozogamicin, Bayer

PALO ALTO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology (ASH) Annual Meeting 2022.

Key Points: 
  • VIP943 combines the unique payload class of kinesin spindle protein inhibitors (KSPi) with a proprietary legumain-cleavable linker.
  • “I am truly excited about the preclinical results for VIP943 and our proprietary payload and linker technology presented at ASH,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • The in vivo AML mouse model results also showed improved efficacy and survival for VIP943 in combination with venetoclax and azacitidine.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Global ANCA Vasculitis Drug Pipeline Market Research Report 2022 Featuring GSK, AstraZeneca, Staidson Biopharmaceuticals, Bristol-Myers Squibb, InflaRx, Chia Tai Tianqing Pharmaceutical & Visterra - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, AstraZeneca, Eosinophilic granulomatosis with polyangiitis, NDA, II, Technology, Benralizumab, Asthma, Survival, Awareness, Macrophage, Disease, Signal transduction, Basophil, Vasculitis, MedImmune, GlaxoSmithKline, ANCA, FDA, Therapy, Eosinophil, News, III, Clinical trial, Immunoglobulin G, Microscopic polyangiitis, Acquisition, Discovery, Patient, Pharmaceutical industry

The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "ANCA Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ANCA Vasculitis pipeline landscape.
  • A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines.
  • The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development.

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Retrieved on: 
Friday, July 22, 2022
Revelation, GLOBE, Allergic rhinitis, Immunity, Degenerative disease, Trial of the century, Forward-looking statement, SAN, SEC, EMA, Private Securities Litigation Reform Act, Basophil, Risk, Safety, COVID-19, NASDAQ, Pollen, T helper cell, Disease, FDA, SPAC, Vaccination, CCR3, Eosinophil, Pharmaceutical industry, Vaccine

This includes no reduction in allergy symptoms (Total Nasal Symptom Score) and no increase in peak nasal inspiratory flow versus placebo.

Key Points: 
  • This includes no reduction in allergy symptoms (Total Nasal Symptom Score) and no increase in peak nasal inspiratory flow versus placebo.
  • The study enrolled two cohorts: one cohort received study drug prior to nasal allergen challenge (the prophylactic cohort) and the second cohort received study drug after the nasal allergen challenge (the treatment cohort).
  • The Phase 1b, randomized, double-blind, placebo-controlled, crossover study design was conducted in Australia.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Retrieved on: 
Thursday, July 14, 2022
People, Allergic rhinitis, Disease, Allergen, Eosinophil, SEC, Safety, Basophil, SPAC, NASDAQ, Nasal congestion, Vaccination, Immunity, Sneeze, T helper cell, Risk, Mouth, EMA, Patient, SAN, Allergy, GLOBE, Atmosphere, COVID-19, Media, Degenerative disease, Sinusitis, Private Securities Litigation Reform Act, Nose, Trial of the century, Polyp (medicine), Forward-looking statement, CCR3, FDA, Quality of life, Pollen, Revelation, Pharmaceutical industry, Online shopping, Vaccine

Key exploratory endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.

Key Points: 
  • Key exploratory endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.
  • Allergic rhinitis, or hay fever, is an allergic reaction to tiny particles in the air called allergens.
  • Allergic rhinitis can lead to complications in some cases including nasal polyps, sinusitis, and middle ear infections.
  • REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis, and is currently being evaluated as a treatment for allergic rhinitis in a Phase 1b CLEAR study.